The B2M Knockout SK-OV-3 Polyclonal Cells consist of a polyclonal population of SK-OV-3 cells modified via CRISPR/Cas9-mediated disruption of the B2M gene, which encodes beta-2-microglobulin (??2M). This product provides a heterogeneous knockout cell pool, enabling functional studies of B2M loss in the context of human ovarian adenocarcinoma. The polyclonal format avoids biases associated with single-cell clones and reflects the diversity of editing outcomes achieved within the bulk population.
The parental SK-OV-3 cell line is an adherent epithelial cell line derived from a malignant ovarian adenocarcinoma of a female patient. These cells serve as an established model for ovarian cancer research, exhibiting characteristics consistent with high-grade serous ovarian carcinoma. SK-OV-3 cells are widely employed to investigate tumor biology, drug responses, and immune interactions in ovarian cancer.
B2M encodes ??2-microglobulin, a critical subunit of major histocompatibility complex (MHC) class I molecules. ??2M non-covalently associates with the HLA class I heavy chain and the peptide-loading complex, comprising TAP1, TAP2, tapasin, calreticulin, and ERp57, to facilitate stable cell-surface expression of MHC class I. This complex presents intracellular peptides to CD8+ T cells, thereby triggering adaptive immune responses. B2M expression is transcriptionally upregulated by IFN-?? signaling through the JAK-STAT pathway, with key transcription factors including STAT1, IRF1, NLRC5, and NF-??B. Beyond immune function, ??2M also interacts with HFE to regulate iron homeostasis, and associates with non-classical MHC class I-like molecules such as CD1, MR1, and FcRn, underscoring its diverse roles.
In SK-OV-3 ovarian cancer cells, B2M knockout ablates MHC class I surface expression, mimicking a common immune evasion mechanism observed in human tumors. Loss of ??2M impairs antigen presentation to CD8+ T cells, reducing cytotoxic T cell recognition and facilitating tumor escape from immune surveillance. This model is thus valuable for dissecting mechanisms of ovarian cancer immune evasion and for evaluating therapeutic strategies that aim to restore or bypass MHC class I-dependent immunity, such as checkpoint inhibitors, adoptive T cell therapy, or NK cell-based approaches. Additionally, disruption of iron homeostasis pathways may contribute to altered cellular metabolism within the tumor microenvironment.
The B2M Knockout SK-OV-3 Polyclonal Cells are suitable for a range of experimental applications, including Western blotting, flow cytometry for MHC class I surface expression, RT-qPCR, immunofluorescence, and T cell cytotoxicity assays. These cells support tumor immune evasion studies, ovarian cancer immunotherapy research, drug screening for immune checkpoint inhibitors, and functional analyses of MHC class I antigen presentation pathways. Their use can be extended to RNA-seq profiling, ELISA-based quantification of IFN-?? responses, and drug sensitivity assays to assess immunomodulatory compounds. For additional technical information or to discuss your specific project needs, please contact Ascent Research.
